KMD Bioscience Co., Ltd.
400-621-6806
2023-08-31 Hits(253)
The transfer of surface molecules between cells by trogocytosis challenges the concept of cell type-unique surface markers and indicates that monoclonal antibodies used for therapeutic purposes may be less specific than previously thought. Furthermore, trogocytosis may transfer functional properties to new cell types. This process could be used experimentally to trace disease-relevant cell–cell interactions.
Owing to their efficacy and specificity, monoclonal antibodies (mAbs) are now widely used to treat various diseases. For example, antibodies against the B cell lineage marker CD20, such as rituximab, ocrelizumab, ofatumumab or ublituximab, are well established for clinical use1. Given that CD20 was assumed to be uniquely expressed on B cells, these mAbs were first used as a treatment for B cell lymphoma. Today, B cell-depleting anti-CD20 is approved for various diseases involving B cells, such as rheumatoid arthritis and multiple sclerosis (MS).
If you want to leam more about the aricles. please visit：https://www.nature.com/articles/s41577-023-00920-7
FL-4, Building A5, International Enterprise Community, Tianjin, China
Email：info@kmdbioscience.com
Hot Line： +1-315-239-3085
Technical Support：sales@kmdbiosci.com